Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction.
OBJECTIVE
To identify factors that contribute to patient drop-out rates from an intracavernous auto-injection programme for erectile dysfunction.


METHODS
Forty-seven patients who had been successfully treated with intracavernous vasoactive agents but who subsequently failed to attend follow-up appointments were included in the study. Each patient completed a self-administered questionnaire.


RESULTS
Thirty (64%) completed questionnaires were returned. The reasons for withdrawal from treatment are outlined.


CONCLUSIONS
The majority of patients who discontinued intracavernous therapy did so for reasons unrelated to treatment associated problems.
Armstrong
D K
DK
Department of Genitourinary Medicine, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
Convery
A G
AG
Dinsmore
W W
WW
D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage; D010352:Patient Dropouts; D017060:Patient Satisfaction; D010409:Penile Diseases / Q000188:drug therapy*; D010410:Penile Erection / Q000187:drug effects; D010646:Phentolamine / Q000008:administration & dosage; D012648:Self Care; D016312:Treatment Refusal
D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine